Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.56 |
| ▸ | CCR5 | P51681 | 16/20 | 0.46 |
| ▸ | CCR7 | P32248 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968866 | 0.99 | CCR2 (0.55) | CCR2CCR5CCR7CXCR3CXCR5 | |
| SCHEMBL7970211 | 0.98 | CCR2 (0.54) | CCR2CCR5CCR7CXCR3CXCR5 | |
| SCHEMBL30227439 | 0.97 | CCR2 (0.56) | CCR2CCR5CCR7CXCR3CXCR5 | |
| SCHEMBL3036593 | 0.97 | CCR2 (0.56) | CCR2CCR5CCR7CXCR3CXCR5 | |
| SCHEMBL3036000 | 0.97 | CCR2 (0.58) | CCR2CCR5CCR7CXCR3CXCR5 | |
| Hydrochloric Acid SCHEMBL7931139 | 0.97 | CCR2 (0.55) | CCR2CCR5CCR7CXCR3CXCR5 | |
| SCHEMBL7970522 | 0.96 | CCR2 (0.56) | CCR2CCR5CCR7CXCR3CXCR5 | |
| SCHEMBL3039378 | 0.95 | CCR2 (0.58) | CCR2CCR5CCR7CXCR3CXCR5 | |
| Sulfuric Acid SCHEMBL7972067 | 0.95 | CCR2 (0.53) | CCR2CCR5CCR7CXCR3CXCR5 | |
| SCHEMBL7969651 | 0.95 | CCR2 (0.53) | CCR2CCR5CCR7CXCR3CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | claimed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | claimed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-8034921-B2 | Chemokine receptors (CCR5); double stranded RNA; gene knockout | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| US-20030078189-A1 | Medicinal compositions for oral use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1236476-A1 | MEDICINAL COMPOSITIONS FOR ORAL USE | Takeda Chemical Industries, Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154016-A1 | Preventives for hiv infection | CCR5, CCR2, CCR1 | CCR2 2/4885CCR5 1/4885CCR7 17/4885 |
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | CCR2 3/4885CCR5 1/4885CCR7 17/4885 |
| US-20030078189-A1 | Medicinal compositions for oral use | CCR5, CXCR3, CCL5 | CCR2 23/4885CCR5 1/4885CCR7 6/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | CCR2 3/4885CCR5 9/4885CCR7 13/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | CCR2 3/4885CCR5 9/4885CCR7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.